LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

Kodu・Aktsiate loetelu・Denali Therapeutics Inc

Denali Therapeutics Inc

Suletud

SektorTervishoid

18.85 4.03

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

18.03

Max

19.16

Põhinäitajad
By Trading Economics
Sissetulek	102K -128M
Aktsiakasum	-0.69
Töötajad	507
EBITDA	-9.8M -135M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+98.29% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	7. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-42M 2.9B
Eelmine avamishind	14.82
Eelmine sulgemishind	18.85

Uudiste sentiment

By Acuity

50%

159 / 345 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

13.355 / 16.44 Toetus ja vastupanu

Denali Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

20. mai 2026, 23:31 UTC

Kuumad aktsiad

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

20. mai 2026, 22:52 UTC

Suurimad hinnamuutused turgudel

Osisko Shares Fall on Planned Convertible Notes Offering

20. mai 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20. mai 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

20. mai 2026, 23:44 UTC

Tulu

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

20. mai 2026, 23:35 UTC

Market Talk

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

20. mai 2026, 23:30 UTC

Market Talk

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

20. mai 2026, 23:17 UTC

Market Talk

Global Equities Roundup: Market Talk

20. mai 2026, 23:17 UTC

Market Talk

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

20. mai 2026, 23:15 UTC

Market Talk

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

20. mai 2026, 23:14 UTC

Tulu

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

20. mai 2026, 23:02 UTC

Market Talk

KMD Brands Faces Two Testing Hurdles -- Market Talk

20. mai 2026, 22:57 UTC

Market Talk

Infratil's Other Assets Deserve Attention, Too -- Market Talk

20. mai 2026, 22:57 UTC

Market Talk

Global Energy Roundup: Market Talk

20. mai 2026, 22:57 UTC

Market Talk

Global Equities Roundup: Market Talk

20. mai 2026, 22:51 UTC

Market Talk

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

20. mai 2026, 22:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20. mai 2026, 22:27 UTC

Market Talk

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

20. mai 2026, 22:14 UTC

Market Talk

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

20. mai 2026, 22:10 UTC

Tulu

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

20. mai 2026, 22:00 UTC

Tulu

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

20. mai 2026, 21:38 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

20. mai 2026, 21:27 UTC

Tulu

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

20. mai 2026, 21:20 UTC

Tulu

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

20. mai 2026, 21:19 UTC

Tulu

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

20. mai 2026, 21:18 UTC

Tulu

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

20. mai 2026, 21:17 UTC

Tulu

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

20. mai 2026, 21:17 UTC

Tulu

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

20. mai 2026, 21:17 UTC

Tulu

Nvidia's Vera CPU Opens New $200B Market, CFO Says

20. mai 2026, 21:16 UTC

Tulu

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Denali Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

98.29% tõus

12 kuu keskmine prognoos

Keskmine 35.91 USD 98.29%

Kõrge 42 USD

Madal 23 USD

Põhineb 14 Wall Streeti analüütiku instrumendi Denali Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

14 ratings

Osta

Hoia

Müü

Põhineb 14 analüütiku instrumendi Denali Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

13.355 / 16.44Toetus ja vastupanu

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

All events are bearish.

Sentiment

By Acuity

159 / 345 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.